Diagnostic accuracy of contrast-enhanced ultrasound for detecting renal cancer: a systematic review and meta-analysis.

Med UltrasonApr 30, 2026 (epub)
Clinical ResearchNephrologyUrology

Renfan Xu, Yunqi He, Xianghuan Xie et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) for differentiating renal cancers from benign masses in a population of 4,530 renal masses. The study found a pooled sensitivity of 0.94 and specificity of 0.85, indicating CEUS is a reliable diagnostic tool, especially for cystic renal masses.

Key findings

  • Pooled sensitivity of CEUS for detecting renal cancer was 0.94 (0.91-0.96).
  • Pooled specificity of CEUS was 0.85 (0.79-0.89).
  • CEUS showed higher sensitivity for cystic masses (0.99) compared to solid masses (0.88).
  • The overall accuracy of CEUS was 0.95 (0.93-0.97).

Why it matters

The findings suggest that CEUS is a highly accurate method for distinguishing between malignant and benign renal masses, which can aid clinicians in making informed decisions regarding patient management and treatment options.

Source

PubMed · PMID 42227142

Published in Med Ultrason. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.